Faeth Therapeutics has raised $25 million to advance its PIKTOR Phase 2 trial for endometrial cancer, building on promising early clinical results and aiming to reshape cancer treatment strategies.

Target Information

Faeth Therapeutics is a clinical-stage biotechnology company specializing in therapies that target tumor metabolism. The company has recently announced advancements in its lead PIKTOR regimen for treating endometrial cancer, which comes alongside a new capital raise of $25 million. This funding brings the total capital raised by Faeth to $92 million. The emphasis of their work is on developing innovative strategies to combat cancer by systematically addressing the metabolic pathways involved in tumor growth.

Recent clinical data highlighted an 80% overall response rate among endometrial cancer patients participating in a phase 1b study using a combination of serabelisib and sapanisertib (the PIKTOR regimen) with paclitaxel. Patients exhibited a median progression-free survival of 11 months, which significantly surpasses historical averages associated with traditional chemotherapy treatments.

Industry Overview

Endometrial cancer represents one of the most pressing areas of need among solid tumors due to its increasing incidence and the significant challenges associated with treatment. It is shaped primarily by the PI3K/AKT/mTOR signaling pathway, a target that has proven